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Abstract
Background: Tumour necrosis factor-a (TNF-a) is a pleiotropic pro-inflammatory cytokine, which is rapidly
upregulated in the brain after injury. TNF-a acts by binding to its receptors, TNF-R1 (p55) and TNF-R2 (p75), on the
cell surface. The aim of this study was first to investigate if there is altered expression of TNF-a and TNF-a
receptors in cerebral artery walls following global or focal ischemia, and after organ culture. Secondly, we asked if
the expression was regulated via activation of the MEK-ERK1/2 pathway.
Methods: The hypothesis was tested in vivo after subarachnoid hemorrhage (SAH) and middle cerebral artery
occlusion (MCAO), and in vitro by organ culture of isolated cerebral arteries. The localization and amount of TNF-a,
TNF-a receptor 1 and 2 proteins were analysed by immunohistochemistry and western blot after 24 and 48 h of
organ culture and at 48 h following SAH or MCAO. In addition, cerebral arteries were incubated for 24 or 48 h in
the absence or presence of a B-Raf inhibitor (SB386023-b), a MEK- inhibitor (U0126) or an NF-B inhibitor (IMD-
0354), and protein expression evaluated.
Results: Immunohistochemistry revealed enhanced expression of TNF-a, TNF-R1 and TNF-R2 in the walls of
cerebral arteries at 48 h after MCAO and SAH compared with control. Co-localization studies showed that TNF-a,
TNF-R1 and TNF-R2 were primarily localized to the cell membrane and the cytoplasm of the smooth muscle cells
(SMC). There was, in addition, some expression of TNF-R2 in the endothelial cells. Immunohistochemistry and
western blot analysis showed that these proteins were upregulated after 24 and 48 h in culture, and this
upregulation reached an apparent maximum at 48 h of organ culture. Treatment with U0126 significantly reduced
the enhanced SMC expression of TNF-a, TNF-R1 and TNF-R2 immunoreactivities after 24 and 48 h of organ culture.
The Raf and NF-B inhibitors significantly reduced organ culture induced TNF-a expression while they had minor
effects on the TNF-a receptors.
Conclusion: The present study shows that cerebral ischemia and organ culture induce expression of TNF-a and its
receptors in the walls of cerebral arteries and that upregulation is transcriptionally regulated via the MEK/ERK
pathway.
Background
Stroke is a serious neurological disease and a leading
cause of death and severe disability in the world [1].
There are two major kinds of stroke: ischemic stroke
and hemorrhagic stroke. Both are associated with dis-
ruption of the blood flow to the brain with rapid deple-
tion of cellular energy and glucose, resulting in ionic
disturbances [2,3]. This initiates a complex process that
includes release of excitatory neurotransmitters and acti-
vation of apoptotic pathways. Several investigators have
shown that inflammation evolves within a few hours
after cerebral ischemia. This inflammatory reaction
involves accumulation of neutrophils, monocytes and
leukocytes in the ischemic brain in animal models and
in human focal stroke [3,4]. There is an early accumula-
tion of neutrophils in the brain and transmigration of
adhesion molecules that are associated with cytokine
signaling. Stroke induces production and release of
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cytokines such as tumor necrosis factor-a (TNF-a),
interleukin-1ß (IL-1ß), interleukin-6 (IL-6), and induci-
ble nitric oxide synthase (iNOS), by a variety of acti-
vated cell types; endothelial cells, microglia, neurons,
leukocytes platelets, monocytes, macrophages and fibro-
blasts [3,4]. We have found increased expression of
iNOS and cytokines after middle cerebral artery occlu-
sion (MCAO) [5] and after subarachnoid hemorrhage
(SAH) [6] localized in smooth muscle cells of cerebral
arteries and in the walls of associated intracerebral
microvessels.
TNF-a is a pleiotropic cytokine produced by many
cell types, and is involved in blood-brain barrier,
inflammatory, thrombogenic, and vascular changes
associated with brain injury [7]. TNF-a has been sug-
gested to stimulate angiogenesis following ischemia
through induced expression of angiogenesis-related
genes [8,9]. It is known as a strong immunomediator
and pro-inflammatory cytokine, which is rapidly upre-
gulated in the brain after injury and is associated with
necrosis or apoptosis [10]. TNF-a effects are mediated
via two receptors, TNF-R1 (p55) and TNF-R2 (p75), on
the cell surface [11]. TNF-R1 is expressed on all cell
types and can be activated by both membrane-bound
and soluble forms of TNF-a. This is a major signaling
receptor for TNF-a. The TNF-R2 is expressed primar-
ily on hemopoietic and endothelial cells, responds to
the membrane-bound form of TNF-a, and mediates
limited biological responses [11]. TNF-a and its recep-
tors may activate the nuclear factor-B (NF-B) path-
way, which in turn may inhibit TNF-a-induced cell
death [12]. NF-B is a pivotal transcriptional factor
down-stream of MAPK and PKC pathways and its
activation is essential for controlling the expression of
several genes involved in inflammation and cell prolif-
eration [13,14]. Increased TNF-a level has been
observed in brain tissue, plasma and cerebrospinal fluid
in Alzheimer’s disease, multiple sclerosis and Parkin-
son’s disease [15-17].
The present study aimed to address two questions:
First, is the expression of TNF-a, TNF-R1 and TNF-R2
altered in cerebrovascular smooth muscle cells (SMCs)
following MCAO, SAH and organ culture? Second,
what intracellular signaling events are involved in regu-
lating the expression of these molecules? This was
examined by in vitro application of signal transduction
blockers, such as the MEK/ERK1/2 inhibitor U0126,
the B-Raf inhibitor SB3860-b, and the NF-B inhibitor
IMD-0354 [18,19]. The studies included an analysis of
the levels of expression of TNF-a, TNF-R1 and TNF-
R2 in cerebral arteries under the different experimental
conditions by both immunofluorescence and western
blot.
Materials and methods
Middle cerebral artery occlusion
Male Wistar-Hanover rats (Møllegaard Breeding Centre,
Copenhagen, Denmark), weighing approximately 300-
350 g (n = 6 per group), were obtained from Harlan
Horst, the Netherlands. The animals were housed under
controlled temperature and humidity with free access to
water and food. The experimental procedures were
approved by the Lund University Animal Ethics Com-
mittee (M43-07). Anaesthesia was induced using 4.5%
halothane in N2O:O2 (70%:30%) and thereafter the ani-
mals were kept anaesthetized through a mask with 1.5%
halothane during the operation. To confirm proper
occlusion of the right MCA a laser-Doppler probe (Peri-
med, Järfälla, Sweden) was fixed on the skull (1 mm
posterior to the bregma and 6 mm from the midline on
the right side) to measure regional cortical blood flow.
A polyethylene catheter was inserted into a tail artery to
measure the mean arterial blood pressure, pH, pO2,
pCO2, and plasma glucose. A rectal temperature probe
connected to a homeothermal blanket was used to
maintain body temperature at 37°C during the proce-
dure. An intraluminal filament technique was used to
induce transient MCAO, previously described in detail
by Memezawa [20]. The resulting occlusion was visible
by laser Doppler flowmetry as an abrupt 80-90% reduc-
tion of cerebral blood flow. Two hours after MCA
occlusion, the rats were briefly reanesthetized to allow
withdrawal of the filament to achieve reperfusion and
normalization of flow. At 48 h post MCA occlusion, the
rats were anesthetized and decapitated, the brains were
removed and the MCAs were harvested. The right cere-
bral artery had been subjected to cerebral ischemia and
the left served as a control (see below for details). The
infarct volume, neurological score and physiological
parameters were calculated and published in previous
studies [21,22]. There were no significant differences in
physiological parameters between the different treatment
groups, such as blood pressure, blood gases, tempera-
ture, plasma glucose, and body weight. We observed an
infarct volume (24.8 ± 2% of total cerebrum in the
MCAO group) and evaluated the neurological score just
before animal sacrifice (MCAO group, 4.0 ± 0.2 versus
sham-operated animals with no visible defects resulting
in a score of 0) [21,22].
Rat subarachnoid hemorrhage model
Subarachnoid hemorrhage was induced by a model ori-
ginally devised by Svendgaard et al [23] and described in
detail by Prunell et al [24]. Male Sprague-Dawley rats
(n = 6 per group) weighing approximately 350-400 g
were anaesthetized using 5% halothane (Halocarbon
Laboratories, River Edge, New Jersey) in a N2O:O2
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mixture (ratio 30:70). All animal experiments were per-
formed following the national laws and guidelines and
were approved by the Danish Animal Experimentation
Inspectorate and the Ethics Committee for Laboratory
Animal Experiments at the University of Lund. The rats
were intubated and artificially ventilated with inhalation
of 0.5-1.5% halothane in a N2O:O2 mixture (ratio 70:30)
during the surgical procedure. The depth of anaesthesia
was carefully monitored and the respiration checked by
regularly withdrawing arterial blood samples for blood
gas analysis (Radiometer, Copenhagen, Denmark). A
temperature probe was inserted into the rectum of each
rat to record the body temperature, which was main-
tained at 37°C by a heating pad. An arterial catheter to
measure blood pressure was placed in the tail artery,
and a catheter to monitor intracranial pressure (ICP)
was placed in the subarachnoid space under the suboc-
ciptal membrane. At either side of the skull, two laser-
Doppler flow probes were placed over either hemisphere
to measure cortical cerebral blood flow (CBF). Finally, a
27 G blunt canula with side hole was introduced 6.5
mm anterior to bregma in the midline at an angle of 30°
to the vertical using a stereotactic frame. After 30 min
of equilibration of the animal, 250 μl blood was with-
drawn from the tail catheter and injected intracranially
at a pressure equal to the mean arterial blood pressure
(MABP) (80-100 mmHg). Subsequently, the rat was kept
under anaesthesia for another 60 minutes to allow
recovery from the cerebral insult after which catheters
were removed and incisions closed. For a more detailed
description, see previous studies [6,25]. During the
recovery period, the rat was monitored regularly, and if
it showed severe distress, the animal was euthanized (8%
mortality). In addition, a series of sham-operated rats
were prepared. They went through exactly the same
procedure as described above except that no blood was
injected intracisternally. The physiological parameters
and cerebral blood flow have been reported before [6].
In that study, we observed no statistical difference in
physiologic parameters among the groups (sham, SAH).
As a result of the injection of blood, the cortical blood
flow dropped in both hemispheres to 14 ± 5% of the
resting flow and the intracranial pressure increased from
12 ± 2 to 121 ± 9 mmHg. These values normalised
within 30 min [6]. There was a significant decrease in
CBF as measured at 48 h in the SAH group (63 ± 2 mL
per 100 g per minute; P < 0.05) as compared with the
control group (140 ± 6 mL per 100 g per minute; P <
0.05) and animals from the SAH group showed a reduc-
tion in regional CBF in 16 of the 18 brain regions exam-
ined as compared with the control (sham) group [6].
Following the procedure described, harvesting of vessels
was done at 48 h post SAH (see below for details).
Harvesting cerebral arteries and brain tissue
After 48 hours of observation, MCAO, sham and SAH
rats were anaesthetized using CO2 and decapitated. The
brains were removed and immersed in ice-cold bicarbo-
nate buffer solution. The right and left MCAs, and the
basilar artery (BA) were dissected out using a dissection
microscope, snap frozen, and stored at -80°C for
immunohistochemistery.
Tissue preparation and organ culture
A total of 111 Male Wistar Hannover rats (Møllegaard
Breeding Center, Copenhagen, Denmark), weighing 350
to 420 g, were used for organ culture. The animals were
anesthetized with CO2 and decapitated. The brains were
quickly removed and chilled in ice-cold bicarbonate buf-
fer solution. The BA, the right and left MCAs, and the
circle of Willis were removed and dissected free from
the brain and surrounding tissue under a dissection
microscope. The artery segments were placed individu-
ally into wells of a 12-well plate with 2 ml serum-free
Dulbecco’s modified Eagle’s medium (DMEM) [26].
Incubation was performed at 37°C in humidified 5%
CO2 in air for 24 or 48 h in the presence or absence of
the intracellular signal inhibitors. The arteries were
transferred into new wells containing fresh medium
every 24 h. After 24 or 48 h, the vessels were snap fro-
zen and stored at -80°C for immunohistochemistery and
western blot.
Buffers, chemicals and drugs
The specific inhibitors used included: an IkB kinase 2
(IKK-2) inhibitor IMD-0354 (N-(3, 5-Bis-trifluoro-
methylphenyl)-5-chloro-2-hydroxybenzamide) (30 nM)
[27], a specific MEK1/2 inhibitor U0126 (10 μM) and a
specific B-Raf inhibitor SB386023-b (10 μM) [28]. IMD-
0354 and U0126 were obtained from Sigma (St Louis,
MI, U.S.A) and SB386023b was a generous gift from Dr.
A. Parsons at GlaxoSmithKline (GSK), UK. All inhibitors
were dissolved in dimethylsulfoxide (DMSO) and further
diluted in saline solution to the final concentrations
used in the experiments. The bicarbonate buffer solu-
tion was of the following composition (mM): 119 NaCl,
15 NaHCO3, 4.6 KCl, 1.2 MgCl2, 1.2 NaH2PO4, 1.5
CaCl2 and 5.6 glucose. Dulbecco’s modified Eagle’s med-
ium (DMEM) contained L-glutamine (584 mg/L) and
was supplemented with penicillin (100 U/ml) and strep-
tomycin (100 μg/ml) (Gibco BRL, Paisley, UK).
Immunohistochemistry
Cerebral arteries from MCAO, SAH, sham, fresh,
culture (24 and 48 h) and culture + inhibitors were
placed into Tissue TEK (Gibo, Invitrogen A/S, Taastrup,
Denmark), frozen on dry ice and sectioned into 10-μm
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thick slices in a cryostat (Microm HM500 M; Thermo
Scientific, Walldorf, Germany). Three sections were col-
lected and placed on each microscope slide (Menzel,
Branuschweig, Germany) Mounted sections were fixed
for 10 minutes in ice-cold acetone (-20°C) and then
rehydrated in phosphate buffer solution (PBS) contain-
ing 0.3% Triton X-100 for 15 min. The sections were
permeabilized and blocked for 1 h in blocking solution
containing PBS, 0.3% TritonX-100, 1% bovine serum
albumin (BSA) and 5% normal donkey serum, and
then incubated over night at 4°C with the following pri-
mary antibodies: rabbit polyclonal to TNF-a (Abcam,
ab66579) diluted 1:500, rabbit polyclonal to TNF-a
receptor 1 (Abcam, ab19139) diluted 1:1800, and rabbit
polyclonal to TNF-a receptor 2 (Abcam, ab15563)
diluted 1:50. All primary antibodies were diluted in PBS
containing 0.3% Triton X-100, 1% BSA, and 2% normal
donkey serum. Sections were subsequently incubated for
1 h at room temperature with secondary Cy™2-conju-
gated donkey anti-rabbit (711-165-152; Jackson Immu-
noResearch, Europe Ltd., Suffolk, UK) diluted 1:200 in
PBS containing 0.3% Triton X-100 and 1% BSA. Finally,
the sections were washed with PBS and mounted with
anti-fading Vectashield mounting medium (Vector
Laboratories Inc., Burlingame, CA, USA). Immunoreac-
tivity was visualized using an epifluorescence micro-
scope (Nikon 80i; Tokyo, Japan) at the appropriate
wavelengths and photographed with an attached Nikon
DS-2Mv camera. The same procedure was used for the
negative controls except that either the primary or the
secondary antibody was omitted to evaluate autofluores-
cence and non-specific secondary antibody binding
levels.
Double immunofluorescence
Double immunofluorescence labeling was performed for
TNF-a, TNF-R1 or TNF-R2 and smooth muscle actin, a
selective smooth muscle cell marker. For the latter, a
mouse anti-rat smooth muscle actin antibody (SC-
53015; Santa Cruz Biotechnology, Inc, Santa Cruz, CA)
was used at 1:200, diluted in PBS containing 0.3% Triton
X-100, 1% BSA, and 2% normal donkey serum. The sec-
ondary antibodies were Cy™2- conjugated donkey anti-
rabbit (Jackson ImmunoResearch, Europe Ltd. Suffolk,
UK) diluted 1:200 and Texas Red-labeled donkey anti-
mouse (Jackson ImmunoResearch, Europe Ltd. Suffolk,
UK) diluted 1:300 in PBS containing 0.3% Triton X-100
and 1% BSA. The sections were mounted with Vecta-
shield mounting medium with 4’, 6-diamidino-2-pheny-
lindole (DAPI) (Vector Laboratories Inc., Burlingame,
CA, USA). The antibodies were detected at the appro-
priate wavelengths using a Nikon confocal microscope
(EZ-cl, Germany).
Western blotting
Cultured MCA, BA and circle of Willis (CW) vessels
were homogenized in cell extract denaturing buffer (Bio-
Source, Carlsbad, CA) containing phosphatase inhibitor
and protease inhibitor cocktails (Sigma, St Louis, MI, U.
S.A). Whole cell lysates were sonicated on ice for 2 min,
centrifuged at 15 000 × g at 4°C for 30 min, and the
supernatants were collected as protein samples. Protein
concentrations were determined using standard protein
assay reagents (Bio-Rad, Hercules, CA) and stored at
-80°C awaiting immunoblot analysis. The protein homo-
genates were diluted 1:1 (v/v) with 2× sodium dodecyl
sulfate (SDS) sample buffer (Bio-Rad). Protein samples
(25-50 μg of total protein) were boiled for 10 min in
SDS sample buffer and separated on 4-15% SDS Ready
Gel Precast Gels (Bio-Rad, USA) for 120 min at 100 V
and transferred to nitrocellulose membranes (Bio-Rad)
at 100 V for 60 min. The membrane was then blocked
for unspecific binding for 1 h at room temperature with
PBS containing 0.1% Tween-20 (Sigma) and 5% non-fat
dried milk, thereafter incubated overnight at 4°C with pri-
mary antibodies: rabbit polyclonal anti TNF-a, TNF-R1
and TNF-R2 (1:250 dilution; Abcam) or mouse polyclonal
anti b-actin (1: 15000 dilution; A5441, Sigma), followed
by incubation with horseradish peroxidase (HRP)-conju-
gated anti-rabbit IgG secondary antibodies (1:40000; GE
Life sciences, Piscataway, NJ) for 1 h at room tempera-
ture. The labelled proteins were developed using the
LumiSensor Chemiluminescent HRP Substrate kit (Gen-
Script Corp., Piscataway, NJ). To detect multiple signals
on a single membrane, the membrane was incubated in
Restore Plus western blot stripping buffer for 5-15 min at
room temperature (Pierce Biotechnology, Inc., Rockford,
IL) between the various labelling procedures.
Calculations and statistical analyses
Fluorescence intensity was measured using the ImageJ
software http://rsb.info.nih.gov/ij/. Measurements were
made in 4 to 6 different areas (located on the clock at 0,
3, 6 and 9 h) for each section and 6 sections from each
rat were evaluated. Thereafter, the mean values of the
intensity per measured area were used (from five differ-
ent rats per group). The increased intensity for the SAH
group was compared to the sham group and for the
MCAO the two sides were compared. Results are
expressed as mean values ± S.E.M (in arbitrary units of
fluorescence intensity). For the arteries in culture, the
mean values were presented as percentage fluorescence
in the culture groups compared to the fresh group,
where the fresh group was set to 100%. The investigator
was blinded to the treatment group of each sample.
For western blot, cerebrovascular protein lysates from
the different groups were compared. Cerebral arteries
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from two rats were pooled for each measurement (n =
8-10 rats in each group; fresh, 24 h incubation, 48 h
incubation, DMSO + 48 h incubation and inhibitors +
48 h incubation). Three independent experiments were
performed in duplicate. The membranes were visualized
using a Fujifilm LAS-4000 Luminescent Image Analyzer
(Stamford, CT), and band intensity was quantified using
Image Gauge Version 4.0 (Fuji Photo Film Co., Ltd.,
Japan). The immunoblot optical density values were pre-
sented as percentage activity in the vehicle and treated
groups compared to the fresh groups, where the fresh
group was set to 100%.
Data are expressed as the mean ± standard error of
the mean (S.E.M). Statistical analyses were performed
using the nonparametric Kruskal-Wallis with Dunn’s
post hoc test for comparison between more than two
groups and Mann-Whitney test for comparison between
two groups. P-values less than 0.05 were considered sig-
nificant; “n” refers to the number of rats.
Results
Middle cerebral artery occlusion
The levels of TNF-a, TNF-R1 and TNF-R2 proteins
expressed in the cerebral arteries after 48 h post MCAO
for 2 h and reperfusion were investigated by immuno-
fluorescence. Microscopic evaluation showed enhanced
expression of TNF-a, TNF-R1 and TNF-R2 in smooth
muscle cells in the MCAO group as compared with
the control group (contralateral non-ischemic side)
(Figure 1a). Measurements of fluorescence intensity con-
firmed the observations and revealed that the increase in
protein expression was significant for all 3 markers:
TNF-a (MCAO arteries 60 ± 5.2 a.u. compared to con-
trol arteries 25 ± 7.3 a.u., P < 0.05), TNF-R1 (MCAO
arteries 66 ± 5 a.u. compared to control arteries 27 ±
2.3 a.u., P < 0.01) and TNF-R2 (MCAO arteries 65 ± 3.4
a.u. compared to control arteries 33 ± 4.3 a.u., P < 0.05)
(Figure 1b).
Subarachnoid hemorrhage
Here we tested the hypothesis that TNF-a and its recep-
tors might be upregulated in the artery wall at 48 h fol-
lowing SAH. Protein levels of TNF-a, TNF-R1 and
TNF-R2 were investigated by immunofluorescence.
Microscopic evaluation and fluorescence intensity mea-
surements revealed that SAH resulted in a more intense
immunoreactive signal corresponding to TNF-a (SAH
arteries 72 ± 4 a.u. compared to sham arteries 30 ± 2.5
a.u., P < 0.05), TNF-R1 (SAH arteries 81 ± 5.6 a.u. com-
pared to sham arteries 39 ± 5.6 a.u., P < 0.01) and TNF-
R2 (SAH arteries 66 ± 6.5 a.u. compared to sham
arteries 25.5 ± 2.3 a.u., P < 0.05) in smooth muscle
cells of MCA and BA as compared to the sham group
(Figures 2a and 2b).
Organ culture
The relative expression levels of TNF-a, TNF-R1 and
TNF-R2 proteins were investigated in cerebral arteries
following 24 or 48 h of culture in the presence of
U0126, SB-386023b, IMD-0354 or control solvent, and
in fresh vessels (non-cultured). Western blot analysis
revealed a significant increase in levels of TNF-a at 24
and 48 h as compared to fresh vessels (145.8 ± 4.8% and
229.2 ± 42.4%, respectively) and of TNF-R1 (193.3 ±
15.7% and 250.4 ± 30.4%, respectively) (Figure 3).
Immunohistochemistry revealed enhanced expression of
TNF-a, TNF-R1 and TNF-R2 both at 24 and at 48 h of
Figure 1 Immunohistochemistry and image analysis of TNF-a,
TNF-R1 and TNF-R2 protein levels in MCA following MCAO. a)
Typical examples that show the increased in TNF-a, TNF-R1 and
TNF-R2 proteins in the artery SMCs wall of rat MCA following
ischemic stroke in comparison to control animals. b) Bar graphs
showing semi-quantification of fluorescence intensity for TNF-a,
TNF-R1 and TNF-R2 in MCA. There were significant increases in the
expression of these proteins in MCAO animals as compared to
control. The results are expressed as mean values ± S.E.M. (in
arbitrary units of fluorescence intensity, a.u.) *P < 0.05 and
**P < 0.01, significant difference between control and MCAO.
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culture, as compared with fresh vessels. The upregula-
tion reached a maximum at 48 h (Figures 4, 5 and 6).
Effect of NF-B, B-Raf and MEK1/2 inhibitors on organ
culture-induced upregulation of TNF-a and its receptors
In order to examine which intracellular signaling path-
ways that may be involved in the upregulation of TNF-
a and its receptors, segments of cerebral arteries were
cultured for 24 or 48 h with medium containing an
IKK-2 inhibitor (IMD-0354, 30 nM), a B-Raf inhibitor
(SB386023-b, 10 μM), the MEK1/2 inhibitor (U0126, 10
μM), or vehicle (same volume). Immunohistochemistry
revealed enhanced expression of TNF-a, TNF-R1 and
TNF-R2 in vehicle-treated samples, particularly at 48 h
of culture (Figures 4, 5, 6 and table 1). This increase
was prevented by treatment with U0126. In addition,
there was a significant reduction in TNF-a immunor-
eactivity after treatment with IMD-0354. IMD-0345 sig-
nificantly decreased also TNF-R1 immunoreactivity at
48 h incubation but not the immunoreactivity to TNF-
R2. Treatment with the upstream B-Raf inhibitor
(SB386023-b) abolished the upregulation of TNF-a and
decreased the enhanced protein expression of TNF-R1
at 48 h (Figures 4, 5 and table 1).
Western blot experiments using lysates from vessels
incubated for 48 h with the inhibitors provided partial
support for the immunohistochemistry results (Figure 7).
A significant reduction in TNFa-like immunoreactivity
was observed after treatment with U0126 as compared
with DMSO + 48 h culture (Figure 7a). The MEK inhibitor
showed a tendency to reduction (but not significant) of the
increase in TNF-R1 after 48 h organ culture (Figure 7b)
and for TNF-R2 (Figure 7c). We only studied TNF-R2
protein expression using western blot analysis after 48 h of
organ culture and since there was no clear signal seen in
fresh group this shows enhanced expression (Figure 7c).
The other two inhibitors showed no significant variations
in expression of TNFa and its receptors (Figure 7).
Double immunofluorescence
TNF-a, TNF-R1 and TNF-R2 proteins were localized
mostly in the cytoplasm and cell membrane of SMCs in
the medial layer of the cerebral artery (studied by
co-localization with actin in the smooth muscle cells).
Additionally, a weak expression of TNF-R2 was
observed in the endothelial cell layer (co-localization
with DAPI, which labels the cell nuclei) (Figure 8).
Discussion
This study is the first to show that cerebral arteries
show similar protein expression profiles with respect
to TNF-a and its receptors in two in vivo cerebral
ischemic models and during in vitro organ culture (used
as a stress model). The upregulation observed here was
Figure 2 Immunohistochemistry and image analysis of TNF-a,
TNF-R1 and TNF-R2 protein levels in BA following SAH. a)
Photographs demonstrating the upregulation of TNF-a, TNF-R1 and
TNF-R2 protein levels in the artery walls of rat basilar artery after
experimental SAH in comparison to sham-operated animals. b) Bar
graphs showing fluorescence intensity for TNF-a, TNF-R1 and TNF-
R2 in BA. There were significant increases in the expression of these
proteins in SAH animals as compared to sham animals The results
are expressed as mean values ± S.E.M. *P < 0.05 and **P < 0.01,
significant difference between sham and SAH.
Figure 3 Western blot showing TNF-a and TNF-R1 protein
expression levels in the cerebral artery after 24 and 48 h
organ culture (OC) as compared with fresh vessel (control). b-
actin was used as a loading control. Data are expressed as mean ±
S.E.M., n = 4. *P < 0.05, **P < 0.01 and *** P < 0.001.
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confirmed by western blot quantification. In support,
quantitative real time-PCR has demonstrated enhanced
expression of TNF-a mRNA in cerebral vessels at 24 h
after SAH, MCAO, organ culture, and in a time study
between 1 to 48 h following SAH [29,30]. An upregula-
tion is observed in the smooth muscle cells of cerebral
arteries, which is regulated by the intracellular MEK-
ERK pathway. The double immunofluorescence analysis
demonstrated that TNF-a and TNF-R1 were primarily
located in the cytoplasm and in the cell membrane of
the SMCs, while the TNF-R2 immunoreactivity was
located in cell membranes of both SMC and endothelial
cells. The present study also showed that organ culture
for 24 and 48 h induces an increased protein expression
of TNF-a, TNF-R1 and TNF-R2 in a time-dependent
manner. We observed enhanced expression of TNF-a
and its receptors in cerebral microvessels following
experimental MCAO and SAH (data not shown), which
is in agreement with a previous report [5].
Several studies have recognized that inflammation is a
key element in the pathophysiology and outcome after
stroke [31]. Cytokines are polypeptides, generally asso-
ciated with inflammation, immune activation and cell
differentiation. TNF-a is a 17-Kd polypeptide cytokine
that may affect growth, differentiation, cell proliferation,
immunomodulation, survival, and the function of a vari-
ety of cells including those of the immune system,
microglia, astrocytes and SMCs [4,11,32-34]. These cel-
lular responses are mediated through two distinct TNF-
a receptors: TNF-R1 is expressed on all cell types,
whereas TNF-R2 is expressed only on cells of the
immune system and on endothelial cells [35].
TNF-a, TNF-R1 and TNF-R2 mRNA levels have been
shown to increase in the brain after both permanent
Figure 4 Immunofluorescence staining for TNF-a; a) in the fresh, organ culture after 24 h incubation, organ culture after 48 h
incubation, 24 h culture + treatment with IMD-0354, 48 h culture + treatment with IMD-0354, 24 h culture + treatment with
SB386023-b, 48 h culture + treatment with SB386023-b, 24 h culture+ treatment with U0126 and 48 h culture + treatment with
U0126. There was a clear increase in TNF-a protein level in the smooth muscle cell layer after 24 and 48 h culture as compared to fresh vessels.
All three inhibitors significantly prevented the enhanced expression of TNF-a protein level in culture for 24 and 48 h. b) Bar graph
demonstrating the fluorescence intensity for TNF-a. The results are expressed as mean values ± S.E.M. *P < 0.05 and **P < 0.01, significant
difference between fresh and culture after 24 and 48 h. §P < 0.05 and §§P < 0.01, significant difference between 48 h organ culture and
treatment with 48 h culture + (IMD-0354, SB386023-b and U0126). #P < 0.05 and ##P < 0.01, significant difference between 24 h organ culture
and treatment with 24 h culture + (IMD-0354, SB386023-b and U0126).
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and transient MCAO in rat and mouse [10,36,37], and
in neuroretina and retinal arteries following ischemia in
pig and mouse [12,38]. In closed head injury, the mRNA
and functional activity (cytotoxicity) of TNF-a are
increased [39] and increased TNF-a protein levels have
been noted by western blot in the brain after stroke
[40]. Thus, there is a correlation between TNF-a and
brain damage.
Several investigators have suggested a role of the
MAPK-MEK-ERK pathway in the regulation of TNF-a
following cerebral ischemia. Studies have shown that
TNF-a can increase the permeability of the blood-brain
barrier (BBB) via activation of the ERK1/2 pathway,
increase the expression of TNF-R1 and TNF-R2, and
that treatment with U0126 inactivates this signaling
pathway and decreases the expression of the TNF
receptors [41,42]. Our findings with the MEK1/2 inhibi-
tor are in concert with this.
Binding of TNF-a to its cell surface receptors results
in activation of mitogen activated protein kinase
(MAPK) which may lead to activation of e.g. two
transcription factors, Activation Protein-1 (AP-1) and
NF-B [43]. NF-B regulates expression of numerous
components of the immune system, which includes pro-
inflammatory cytokines, chemokines, adhesion mole-
cules and inducible enzymes such as inducible nitric
oxide synthase and cycloxygenase-2. Dysregulation of
this signaling may result in inflammatory and autoim-
mune diseases [44]. NF-B proteins are predominantly
located in the cytoplasm, associating with members of
the inhibitory IB family such as IB-a, IB-b, IB-ε.
IB proteins are believed to sequester NF-B in the
Figure 5 Immunofluorescence staining for TNF-R1; a) in the fresh, organ culture after 24 h incubation, organ culture after 48 h
incubation, 24 h culture + treatment with IMD-0354, 48 h culture + treatment with IMD-0354, 24 h culture + treatment with
SB386023-b, 48 h culture + treatment with SB386023-b, 24 h culture+ treatment with U0126 and 48. There was a marked increase in
TNF-R1 protein level in the smooth muscle cell layer after 24 and 48 h culture as compared to fresh vessels. TNF-R1 was significantly decreased
with all three inhibitors at 48 h of organ culture and reduced at 24 h. b) Bar graph demonstrating the fluorescence intensity for TNF-R1. The
results are expressed as mean values ± S.E.M. *P < 0.05 and **P < 0.01, significant difference between fresh and culture after 24 and 48 h. §P <
0.05 and §§P < 0.01, significant difference between 48 h organ culture and treatment with 48 h culture + (IMD-0354, SB386023-b and U0126). #P
< 0.05 and ##P < 0.01, significant difference between 24 h organ culture and treatment with 24 h culture + (IMD-0354, SB386023-b and U0126).
n.s. = not significant.
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cytoplasm by masking its nuclear localization sequences.
Thus, activation of NF-B depends on degradation and
phosphorylation of IB [45].
In this study we have shown for the first time that in
vitro organ culture of isolated cerebral arteries and in
vivo ischemia models (MCAO and SAH) result in
upregulation of TNF-a and TNF-a receptors after 48 h
in cerebral vessels walls. Previous studies have revealed
that organ culture of cerebral arteries results in upregu-
lation of inflammatory factors such as cytokines and
matrix metalloproteinases (MMPs) after 24 h in a way
similar to that seen in ischemia models [29]. In addition,
Figure 6 Immunofluorescence staining for TNF-R2; a) in the fresh, organ culture after 24 h incubation, organ culture after 48 h
incubation, 24 h culture + treatment with IMD-0354, 48 h culture + treatment with IMD-0354, 24 h culture + treatment with
SB386023-b, 48 h culture + treatment with SB386023-b, 24 h culture+ treatment with U0126 and 48. The expression of TNF-R2 increased
in culture with a maximum in 48 h compare to fresh group. UO126 treatment significantly prevented this expression while, both IMD-0354 and
SB386023-b slightly reduced the TNF-R2 protein level. b) Bar graph demonstrating the fluorescence intensity for TNF-R2. The results are
expressed as mean values ± S.E.M. *P < 0.05 and **P < 0.01, significant difference between fresh and culture after 24 and 48 h. §P < 0.05,
significant difference between 48 h organ culture and treatment with 48 h culture + U0126. #P < 0.05, significant difference between 24 h organ
culture and treatment with 24 h culture + U0126. n.s. = not significant.
Table 1 Levels of TNF-a, TNF-R1 and TNF-R2 proteins in the cerebral arteries in fresh vessels, in 24 and 48 h organ
culture, with present and absences of IMD-0354, SB386023-b and U0126
Fresh 24 h OC 48 h OC IMD-0354
+ 24 h OC
IMD-0354
+ 48 h OC
SB386023-b
+ 24 h OC
SB386023-b
+ 48 h OC
U0126
+ 24 h OC
U0126
+ 48 h OC
TNF-a 100 ± 6 126 ± 1* 186 ± 10** 83 ± 7# 119 ± 7§ 77 ± 10# 101 ± 9§ 53 ± 8## 67 ± 9§§
TNF-R1 100 ± 7 139 ± 11* 197 ± 8** 115 ± 6 151 ± 8§ 105 ± 6 143 ± 8§ 118 ± 11 140 ± 6§
TNF-R2 100 ± 9 145 ± 15* 207 ± 14** 122 ± 7 193 ± 8 125 ± 7 194 ± 10 98 ± 8# 170 ± 9§
Values are expressed as percentage of fresh and given as mean values ± S.E.M, n = 5.
*P < 0.05 and **P < 0.01, significant difference between fresh and culture after 24 and 48 h.
§P < 0.05 and §§P < 0.01, significant difference between 48 h organ culture and treatment with 48 h culture + (IMD-0354, SB386023-b and U0126).
#P < 0.05 and ##P < 0.01, significant difference between 24 h organ culture and treatment with 24 h culture + (IMD-0354, SB386023-b and U0126).
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Figure 7 Western blot of TNF-a, TNF-R1 and TNF-R2 protein levels from rat cerebral arteries; after 0 h (fresh), 48 h organ culture (OC)
+ DMSO, 48 h OC + (IMD-0354, SB386023-b or U0126) together with b-actin as loading control are shown. UO126 treatment
significantly decreased the increase protein level of TNF-a after 48 h culture (a). Data are presented as the TNF-a, TNF-R1 and TNF-R2/b-actin
mean optical density ratio relative to fresh (a-b) or vehicle (48 h OC + DMSO) (c). Data are presented as mean S.E.M. *P < 0.05.
Figure 8 Double-immunofluorescence staining for TNF-a, TNF-R1 and TNF-R2 (green) and smooth muscle actin (SMC) (red); triple
staining with DAPI (which labels the cell nuclei; blue) of the cerebral arteries. The enhanced expression of TNF-a and TNF-R1 was located
in the cytoplasm and cell membrane of the smooth muscle cells (yellow color in merge). The TNF-R2 immunoreactivity was located in both SMC
and endothelial layer (white arrows) (merge).
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we have observed that after 24 h organ culture [28] and
in experimental MCAO and SAH at 24 h [29] there is
activation of MAPK cell signaling. We hypothesize that
one major factor behind this is the change in shear
stress which is caused by the rise in intracranial pressure
and the reduction in wall tension in SAH or MCAO,
and the removal of the intraluminal pressure during
the organ culture procedure. We therefore suggest
that organ culture can be used as a method to study
mechanisms involved in enhanced expression of TNF-a
and its receptors in cerebral arteries that occur following
cerebral ischemia.
On the other hand the mechanical stress has been
reported to activate MAPKs [46] and this event result in
the activation of ERK1/2, P38 and JNK signal transdu-
cers. In addition, in a previous study [47] we reported in
a western blot time study of global ischemia that there
was early activation of the ERK1/2 pathway already
within one hour while there was no activation of c-jun
N-terminal kinase (JNK) or p38 at time points before 24
hours. Therefore, in order to elucidate the role of the
intracellular MEK/ERK-NF-B pathway in relation to
upregulation of TNF-a and its receptors, we cultured
cerebral artery segments for 24 or 48 h in the presence
of SB386023-b or U0126 (10 μM), which block the
upstream ERK1/2 signaling, and with IMD-0354 (30
nM), which blocks the downstream transcription factor
NF-B. The specificity of U0126, IMD-0354 and
SB386023-b, in the doses used have been examined
and reported in previous studies [18,19 and 48]. We
observed that the enhanced expression of TNF-a was
significantly reduced by treatment with each of these
inhibitors in the immunohistochemistry part and this
was confirmed for U0126 for the western blot. This is
consistent with earlier work in vivo in which we showed
that (i) SB386023-b following experimental SAH [6],
and (ii) U0126 after MCAO [5] prevented enhanced
cytokine expressions (TNF-a, IL-1b and IL-6). NF-B is
also activated early during organ culture (starting at 1 h)
in rat mesenteric arteries [27]. The specific IKK-2 inhi-
bitor (IMD-0354) has been shown to inhibit NF-B acti-
vation by enhancing the stability of the IB-NF-B
complex [49], thereby preventing the enhanced expres-
sion of TNF-a and its receptors in vascular SMC.
In the present study, by immunohistochemistry we
report that all three inhibitors decreased expression of
TNF-R1 protein at 48 h incubation. In contrast, the
increased expression of TNF-R2 was significantly pre-
vented only by U0126 treatment. The western blot
experiments provided partial support for this by a ten-
dency for inhibition of expression by U0126. One possi-
ble explanation for the difference might be that TNF-R1
contains a death domain in its cytoplasmic region
whereas TNF-R2 lacks this [50]. Activation of TNF-R1
may lead to activation of the death domain, which
activates the Ras and Raf kinases and thereafter phos-
phorylated pERK1/2 promotes activation of NF-B by
degradation of IB. Therefore, blockade of phosphoryla-
tion and activation of this pathway can potentially inhi-
bit the expression of TNF-R1, which correlates with
suppression and inhibition of TNF-a expression [51]. In
contrast, TNF-R2 can also activate NF-B by a non-clas-
sical pathway, which is independent of degradation of
IB [42,52,53]. Administration of U0126 has been
shown to reduce ischemic brain injury via inhibition of
phosphorylated-MEK1/2 and phosphorylated- ERK1/2
expression, and prevents elevation of downstream
transcription factors such as ELK-1, NF-B and AP-1
phosphorylation [54].
Conclusion
Our results show that cerebral ischemia (MCAO, SAH)
and organ culture are associated with enhanced TNF-a,
TNF-R1 and TNF-R2 protein levels in the wall of cere-
bral arteries. In addition, treatment with inhibitors of
the MEK/ERK signaling pathway and NF-B transcrip-
tion factor prevent these enhanced expressions to var-
ious extents. The results suggest that inhibition of TNF
signaling pathways by inhibition of the intracellular
MAPK ERK1/2 pathway may constitute interesting tar-
gets, whereby inflammatory processes elicited following
stroke may be prevented or attenuated.
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